Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

‘Leaps of Faith:’ ICER Meeting Suggests Reimbursement Hurdles For NASH Drugs

02 May 2023

• By Sarah Karlin-Smith

liver — • Source: Shutterstock

Related Content

Wegovy Wins English Funding For Weight Loss As Novo Deals With Supply Issues

08 Mar 2023

ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

16 Feb 2023

Medicare Coverage For Alzheimer’s Drugs: CMS Declines To Revise Restrictions For Class

23 Feb 2023

Intercept, Madrigal Get Ready For NASH Commercialization

02 Mar 2023

Intercept CRL Likely About OCA-Specific Concerns, Not NASH Endpoints

30 Jun 2020

Related Companies

Intercept Pharmaceuticals, Inc.

Additional Topics

United States Drug Review Reimbursement Pricing Debate Commercial Cost Effectiveness Drug Approval Standards Liver & Hepatic BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.